Serum Xylosyltransferase Activity in Diabetic Patients as a Possible Marker of Reduced Proteoglycan Biosynthesis by Götting, Christian et al.
Serum Xylosyltransferase Activity in
Diabetic Patients as a Possible Marker of
Reduced Proteoglycan Biosynthesis
CHRISTIAN G¨ OTTING, PHD
JOACHIM KUHN, PHD
KNUT KLEESIEK, MD
OBJECTIVE — Proteoglycan metabolism is altered in diabetic patients. The xylosyltrans-
ferases (XTs) are the initial and rate-limiting enzymes in the biosynthesis of the glycosamino-
glycan chains in proteoglycans. Here, we analyzed whether the changed proteoglycan
metabolism leads to altered serum XT levels in diabetic patients.
RESEARCH DESIGN AND METHODS — Serum XT activity was determined in 100
diabetic patients and 100 blood donors using a novel high-performance liquid chromatography
electrospray ionization tandem mass spectrometry assay.
RESULTS — Serum XT activities in male and female diabetic patients were signiﬁcantly de-
creased compared with those in the corresponding normoglycemic control subjects (mean  SD:
male patients, 19.3  4.44 mU/l; male nondiabetic control subjects, 26.6  2.79 mU/l; female
patients,18.93.14mU/l;femalenondiabeticcontrolsubjects,21.83.74mU/l;P0.0001).No
signiﬁcant differences were detected between patients with type 1 and type 2 diabetes.
CONCLUSIONS — Our data show decreased XT activity in patients with diabetes, a disease
that is accompanied by an altered proteoglycan biosynthesis.
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D
iabetic patients have been previ-
ously reported as having an al-
tered proteoglycan metabolism,
which results in decreased content of
heparan sulfate proteoglycans in base-
ment membranes (1). Proteoglycans
consist of a core protein to which gly-
cosaminoglycan chains are attached.
Thebiosynthesisoftheglycosaminogly-
can chains is initiated by a xylosylation
of the proteoglycan core protein. Xylo-
syltransferase (XT)-I and -II (enzyme
commission [EC] no. 2.4.2.26) catalyze
the initial and rate-limiting step in gly-
cosaminoglycan biosynthesis and have
been shown to play an important role in
proteoglycan homeostasis (rev. in 2). XT-I
and XT-II are Golgi-resident proteins that
are shed from the Golgi membrane and are
secreted into the extracellular space at-
tached to large proteoglycans. Conse-
quently, XT activity present in blood has
been proposed as a biochemical marker for
the determination of an enhanced proteo-
glycan biosynthesis rate (2).
Hyperglycemia has been shown to
affect a series of cellular processes in-
cluding glycosylation (3,4). In diabetic
patients, the biosynthesis of heparan
sulfate proteoglycans has been found to
be decreased (5,6), and a reduced hepa-
ran sulfate glycosaminoglycan content
has been reported in the arteries of dia-
betic patients (7). Furthermore, the as-
sociation between diabetes and heparan
sulfate glycosaminoglycans and im-
paired organ function has been inten-
sively studied in the kidneys, where
heparan sulfate proteoglycans are im-
portant components of the glomerular
basement membrane (8,9).
RESEARCH DESIGN AND
METHODS— The study cohort com-
prised100unrelatedCaucasiandiabeticpa-
tients (50 male, aged 53  8 years; 50
female, aged 54  7 years) and 100 unre-
lated age- and sex-matched blood donors
with normal blood glucose levels (3.9–5.6
mmol/l).Withinthepatientcohort,35were
type 1 diabetic (17 male, aged 26  12
years; 18 female, aged 29  11 years) and
65 patients were type 2 diabetic (33 male,
aged569years;32female,aged5712
years). The deﬁnition of type 1 and type 2
diabeteswasaccordingtocurrentAmerican
DiabetesAssociationandWorldHealthOr-
ganization recommendations (10). Disease
duration was at least 5 years in all patients.
The experimental design was approved by
the local ethics committee, and all patients
gave informed consent. Blood was drawn
after overnight fast, and determination of
XTactivitywasperformedasdescribedpre-
viously (11). Statistical analysis was per-
formed using the Student’s t test and the
Kolmogoroff-Smirnofftestwhereappropri-
ate. Normality testing for Gaussian distri-
bution of values was performed using the
Ftest,andmultiplelinearregressionanal-
yses were used to assess the independent
roleoftheserumXTactivityaswellassex,
age, A1C, duration of diabetes, and other
serum parameters (alanine aminotransfer-
ase, aspartate aminotransferase, bilirubin,
calcium, cholesterol, cholinesterase, C-re-
active protein, creatine kinase, creatinine,
-glutamyl transferase, HDL cholesterol,
lactatedehydrogenase,LDLcholesterol,po-
tassium, sodium, total protein, triglycer-
ides, urea, and uric acid). P values 0.05
were considered statistically signiﬁcant.
RESULTS— XT activities in male dia-
betic patients (n  50) were signiﬁcantly
reduced in comparison with those in the
control group (P  0.0001). The mean 
SD (90% range) was 19.3  4.44 mU/l
(13.2–26.6) in male diabetic patients and
26.6  2.79 mU/l (18.1–29.1) in nondi-
abetic male control subjects (n  50, re-
spectively) (Fig. 1). XT activities in serum
specimens from female diabetic patients
were also signiﬁcantly decreased com-
paredwiththosefromnondiabeticfemale
control subjects (P  0.0001). In female
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the Institut fu ¨r Laboratoriums-und Transfusionsmedizin, Herz-und Diabeteszentrum Nordrhein-
Westfalen, Universita ¨tsklinik der Ruhr-Universita ¨t Bochum, Bad Oeynhausen, Germany.
Corresponding author: Christian Go ¨tting, cgoetting@hdz-nrw.de.
Received 16 May 2008 and accepted 16 July 2008.
Published ahead of print at http://care.diabetesjournals.org on 23 July 2008. DOI: 10.2337/dc08-0909.
© 2008 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Pathophysiology/Complications
BRIEF REPORT
2018 DIABETES CARE, VOLUME 31, NUMBER 10, OCTOBER 2008diabeticpatients(n50),themeanSD
(90% range) was 18.9  3.14 mU/l
(14.6–24.4) (Fig. 1). In the correspond-
ing group of female nondiabetic control
subjects (n  50), the mean  SD XT
activities (90% range) was calculated as
21.8  3.74 mU/l (15.3–29.2). The se-
rum XT activities did not differ between
patients with type 1 (19.9  3.60 mU/l)
and type 2 diabetes (18.7  3.91 mU/l).
The observed differences in serum XT ac-
tivities remained signiﬁcant after adjust-
ment for sex, age, A1C, duration of
diabetes, and other serum parameters as
listed above. Furthermore, no signiﬁcant
correlation of the serum XT activities and
these parameters was observed.
CONCLUSIONS — In the diabetic
state,areducedbiosynthesisofproteogly-
cans has been described (5,6,12). A de-
crease in the glycosaminoglycan content
has been reported for multiple tissues in-
cluding arteries (7), glomerular basement
membranes, or the endothelium (12).
The associations between hyperglycemia,
glycosaminoglycan concentration, and
impaired organ function have been well
studied in the kidneys (1). These alter-
ations point to those enzymes involved in
the biosynthesis of the glycosaminogly-
can chains and to both their regulation
and enzymatic activity as potential modi-
ﬁers of this process.
XT-IandXT-IIcatalyzetheinitialand
rate-limiting transfer of xylose to selected
serine residues of the proteoglycan core
protein (2). Both enzymes are shed from
theGolgimembraneandarereleasedinto
the extracellular space attached to large
proteoglycans (2,13). Therefore, the XT
activity in body ﬂuids reﬂects the actual
proteoglycan biosynthesis rate. While the
biological role of XT secretion is not un-
derstood,thequantiﬁcationofXTactivity
in the peripheral blood and other body
ﬂuids could be successfully validated as a
markeroftheactualproteoglycanbiosyn-
thesis rate (2).
In the present study, we show for the
ﬁrst time reduced XT activity in diabetes,
adiseaseinwhichareducedproteoglycan
biosynthesis rate has been demonstrated
(7,8,12). This low XT activity is proposed
toresultfromadecreasedenzymebiosyn-
thesis rate or a lowered release from the
Golgi apparatus; however, an increase of
enzyme turnover or an elimination of the
enzyme from the blood stream must also
betakenintoaccount.Furthermore,there
is a signiﬁcant overlap in the XT activities
of diabetic patients and normal subjects
pointing to multiple factors affecting the
individual serum XT activity. The XT ac-
tivity determined in peripheral blood is
supposed to be a mixture of XT-I and
XT-II enzyme activity, as both enzymes
are released into the extracellular space
andsharehighlysimilaracceptorspeciﬁc-
ity. To date, neither immunologic nor en-
zyme activity assays that are suitable for
discriminating between the two XT iso-
forms are available. The future develop-
ment of XT-I – and XT-II–speciﬁc assays
will help to elucidate whether diagnostic
advancementisachievedbyaselectedde-
termination of the XT isoforms.
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Figure 1—Serum XT activities in male and female patients with diabetes (DM) and age- and
sex-matchedcontrolsubjects(C).Theblackbarrepresentsthemeanvalue.TheXTactivitiesofthe
male and female diabetic patients were signiﬁcantly reduced compared with those of the corre-
sponding control cohort (P  0.0001).
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